Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MO-TRANS: Mocravimod as adjunctive and maintenance therapy in AML patients undergoing allogeneic HCT
2024-512752-38-00Phase 3Authorised
- Sponsor
- Priothera
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial in acute myeloid leukemia (AML) comparing Mocravimod arm with Placebo arm (2 arms). Primary endpoint: Relapse-free survival. Planned start Aug 2022; status: authorised.
02
Drugs
mocravimod
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2024-512752-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512752-38-00.